［1］Levin D，Bell S，Sund R，et al.Pioglitazone and bladder cancer risk：A multipopulation pooled，cumulative exposure analysis［J］.Diabetologia，2015，58(3)：493-504.
[2]Malats N，Real FX.Epidemiology of bladder cancer［J］.Hematology/Oncology Clinics，2015，29(2)：177-189.
[3]Fan Y，Shen B，Tan M，et al.TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12［J］.Clinical Cancer Research，2014，20(6)：1531-1541.
[4]Choi W，Porten S，Kim S，et al.Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy［J］.Cancer Cell，2014，25(2)：152-165.
[5]Gangopadhyay A，Nath P，Biswas J.Reduced dose intensity of chemotherapy may not lead to inferior palliation in locally advanced carcinoma of the gall bladder：An experience from a regional cancer centre in Eastern India［J］.Journal of Gastrointestinal Cancer，2015，46(3)：297-300.
[6]Plimack ER，Dunbrack RL，Brennan TA，et al.Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer［J］.European Urology，2015，68(6)：959-967.
[7]Witjes JA，Compérat E，Cowan NC，et al.EAU guidelines on muscle-invasive and metastatic bladder cancer：Summary of the 2013 guidelines［J］.European Urology，2014，65(4)：778-792.
[8]Ismail TM，Bennett D，Platt-Higgins AM，et al.S100A4 elevation empowers expression of metastasis effector molecules in human breast cancer［J］.Cancer Research，2017，77(3)：780-789.
[9]Hansen MT，Forst B，Cremers N，et al.A link between inflammation and metastasis：Serum amyloid A1 and A3 induce metastasis，and are targets of metastasis-inducing S100A4［J］.Oncogene，2015，34(4)：424-435.
[10]She Dongli，Fu Shengjun，Yang Li.Progress of miRNA in bladder cancer［J］.Modern Oncology，2016，24(23)：3841-3843.
[11]Zhai X，Zhu H，Wang W，et al.Abnormal expression of EMT-related proteins，S100A4，vimentin and E-cadherin，is correlated with clinicopathological features and prognosis in HCC［J］.Medical Oncology，2014，31(6)：1-9.
[12]Powles T，Eder JP，Fine GD，et al.MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer［J］.Nature，2014，515(7528)：558-562.
[13]Itesako T，Seki N，Yoshino H，et al.The microRNA expression signature of bladder cancer by deep sequencing：The functional significance of the miR-195/497 cluster［J］.PloS One，2014，9(2)：e84311.
[14]Matsushita R，Seki N，Chiyomaru T，et al.Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer［J］.British Journal of Cancer，2015，113(2)：282-289.
[15]Armstrong DA，Green BB，Seigne JD，et al.MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer［J］.Molecular Cancer，2015，14(1)：194.
[16]Sasaki H，Yoshiike M，Nozawa S，et al.Expression level of urinary microRNA-146a-5p is increased in patients with bladder cancer and decreased in those after transurethral resection［J］.Clinical Genitourinary Cancer，2016，14(5)：e493-e499.
[17]Sabaliauskaité R，Stuopelyté K，Visakorpi T，et al.44-down-regulation of miR-149 in TMPRSS2-ERG gene fusion-positive prostate cancer［J］.European Urology Supplements，2017，16(5)：e2215.
[18]Du W，Ma XL，Zhao C，et al.Associations of single nucleotide polymorphisms in miR-146a，miR-196a，miR-149 and miR-499 with colorectal cancer susceptibility［J］.Asian Pac J Cancer Prev，2014，15(2)：1047-1055.
[19]Si L，Xu L，Yin L，et al.Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the Akt1 signalling pathway［J］.British Journal of Pharmacology，2017，174(7)：553-568.
[20]Gu JY，Tu L.Investigating the role of polymorphisms in miR-146a，-149，and-196a2 in the development of gastric cancer［J］.Genetics and Molecular Research：GMR，2016，15(2)：214-219.
[21]Yang D，Du G，Xu A，et al.Expression of miR-149-3p inhibits proliferation，migration，and invasion of bladder cancer by targeting S100A4［J］.American Journal of Cancer Research，2017，7(11)：2209.